Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

SAN DIEGO and BASEL, Switzerland, Nov. 16 (Korea Bizwire) — Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation cytokine immunotherapies, today announced that it has entered into a license agreement with Livzon Mabpharm, Inc. (“Livzon”), a subsidiary company of Livzon Pharmaceutical Group, to use LZM009, Livzon’s proprietary anti-PD-1 monoclonal antibody currently in late-stage clinical [...]